4.7 Article

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 63, Issue 1, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01801-18

Keywords

Enterobacteriaceae; Gram-negative bacteria; S-649266; cefiderocol; cephalosporin; siderophore

Funding

  1. National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) [UM1AI104681]
  2. Cleveland Department of Veterans Affairs from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [1I01BX001974]
  3. Geriatric Research Education and Clinical Center VISN 10
  4. Shionogi
  5. NIH [R01AI100560, R01AI063517, R01AI072219]

Ask authors/readers for more resources

The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant Acinetobacter baumannii complex, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and Enterobacteriaceae strains was determined by microdilution in iron-depleted Mueller-Hinton broth. The MIC90s against A. baumannii, S. maltophilia, and P. aeruginosa were 1, 0.25, and 0.5 mg/liter, respectively. Against Enterobacteriaceae, the MIC90 was 1 mg/liter for the group harboring OXA-48-like, 2 mg/liter for the group harboring KPC-3, and 8 mg/liter for the group harboring TEM/SHV ESBL, NDM, and KPC-2.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available